Table 3.
Characteristics of cell lines
| NI-1 | C2 | HMC-1.1 | HMC-1.2 | NI-1 xeno-TX* | |
|---|---|---|---|---|---|
| Diameter, size (μM) | 11.2 (±0.7) | 14.3 (±0.2) | 17.7 (±0.7) | 14.5 (±0.4) | 12 (±0.6) |
| Histamine (pg/cell) | 0.12 (±0.06) | 0.3 (±0.17) | 0.76 (±0.46) | 0.4 (±0.08) | n.d. |
| Kit mutation status | 2 SiM (Exon 8) | 48-bp ITD (Exon 11) | V560G (Exon 11) | V560G (Exon 11) | 2 SiM (Exon 8) |
| MiM (Exon 8) | D816V (Exon 17) | 2 MiM (Exon 8) | |||
| 12-bp dup (Exon 8) | 12-bp del (Exon 10) | ||||
| Immunocytochemistry | NI-1 | C2 | HMC-1.1 | HMC-1.2 | NI-1 xeno-TX* |
| CD2 | (+) | (+) | (+) | (+) | (+) |
| CD25 | + | + | + | + | n.t. |
| CD34 | − | − | − | − | − |
| CD117/Kit | +++ | +++ | +++ | +++ | +++ |
| HDC | + | + | ++ | + | n.t. |
| Chymase | − | − | − | − | − |
| Tryptase | + | ++ | +++ | +++ | + |
| Flow cytometry | NI-1 | C2 | HMC-1.1 | HMC-1.2 | NI-1 xeno-TX* |
| CD2 | − | − | − | +++ | − |
| CD9 | +/− | − | +++ | +++ | − |
| CD25 | − | − | − | + | − |
| CD30 | +++ | ++ | n.t. | n.t. | n.t. |
| CD44 | +++ | +++ | +++ | +++ | +++ |
| CD54 | + | − | + | +++ | + |
| CD58 | − | +/− | ++ | +++ | − |
| CD62E | + | − | + | + | + |
| CD62L | − | − | − | − | − |
| CD62P | − | − | − | − | − |
| CD63 | − | − | + | +++ | − |
| CD117/Kit | +++ | +++ | +++ | +++ | +++ |
| CD162 | − | − | +++ | +++ | − |
SiM, single point mutation; HDC, histidine decarboxylase; MiM, missense mutation; bp, base pair; dup, duplication; del, deletion; ITD, internal tandem duplication; n.t., not tested; 0–10%: −; 11–20%: +/−; 21–45%: +; 46–70%: ++; 71–100%: +++.
The histamine content in cell lines was determined by RIA. Immunocytochemistry and flow cytometry were performed using anti-leukocyte antibodies as described in the text.
*
NI-1 xenoTX: NI-1 cells obtained from mast cell tumors developing in NSG mice after xenotransplantation.